CEDRA Corporation
, a division of
Worldwide Clinical Trials
,announces its new company name, Worldwide Clinical Trials Drug Development Solutions. This unified name adds to the continuity and full-service offerings our companies collectively provide.
Worldwide Clinical Trials Drug Development Solutions continues to offer Bioanalytical Sciences and Clinical Research Services, as well as specialized studies to determine the effects of dose, formulation, dosing regimen, drug interactions, genotype, gender and other factors on pharmacokinetics.
Worldwide Clinical Trials and Worldwide Clinical Trials Drug Development Solutions will use their combined medical and scientific expertise to provide service in drug development. Worldwide Clinical Trials specializes in mid-/late-phase, and Worldwide Clinical Trials Drug Development Solutions specializes in bioanalytical/early-phase clinical trials, covering all phases in the clinical trials process.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.